



CODEN [USA]: IAJPB

ISSN : 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**

SJIF Impact Factor: 7.187

Available online at: <http://www.iajps.com>

Research Article

**SIMULTANEOUS ESTIMATION OF FUROSEMIDE &
TRIAMTERENE IN PURE AND PHARMACEUTICAL DOSAGE
FORM BY USING RP-HPLC METHOD.****G.Bhavani*, Dr.Nihar Ranjan Das¹, Dr.K.Balaji¹**

¹department Of Pharmaceutical Analysis, Avanthi Institute Of Pharmaceutical Science
,Gunthapally (V), Hayathnagar (Mandal), Near Ramoji Film City, Ranga Reddy (Dist),
Pincode : 501505

Abstract:

A new, simple, precise, accurate and reproducible RP-HPLC method for Simultaneous estimation of Triamterene and Furosemide in bulk and pharmaceutical formulations. Separation of Triamterene and Furosemide was successfully achieved on a Phenomenex Luna C18 (4.6×250mm, 5μm) particle size or equivalent in an isocratic mode utilizing Acetonitrile: Phosphate Buffer (pH-4.6) (45:55 v/v) at a flow rate of 1.0mL/min and eluates was monitored at 245nm, with a retention time of 2.102 and 3.537 minutes for Triamterene and Furosemide respectively. The method was validated and the response was found to be linear in the drug concentration range of 6μg/mL to 14μg/mL for Triamterene and 18μg/mL to 42μg/mL for Furosemide. The values of the slope and the correlation coefficient were found to be 77824 and 0.999 for Triamterene and 10515 and 0.999 for Furosemide respectively. The LOD and LOQ for Triamterene were found to be 0.6μg/mL and 1.8μg/mL respectively. The LOD and LOQ for Furosemide were found to be 0.8 μg/mL and 2.4μg/mL respectively. This method was found to be good percentage recovery for Triamterene and Furosemide were found to be 100.351 and 100.93 respectively indicates that the proposed method is highly accurate. The specificity of the method shows good correlation between retention times of standard with the sample so, the method specifically determines the analytes in the sample without interference from excipients of tablet dosage forms. The method was extensively validated according to ICH guidelines for Linearity, Range, Accuracy, Precision, Specificity and Robustness.

Keywords: Triamterene and Furosemide, High performance liquid chromatography, Validation.

Corresponding author:**G.Bhavani,**

Department of Pharmaceutical Analysis,
Avanthi Institute Of Pharmaceutical Science,
Gunthapally (V), Hayathnagar (Mandal),
Near Ramoji Film City, Ranga Reddy (Dist), Pincode : 501505.
Email Id- gedalabhavani13@gmail.com

QR code



Please cite this article in press G.Bhavani et al, *Simultaneous Estimation Of Furosemide & Triamterene In Pure And Pharmaceutical Dosage Form By Using Rp-Hplc Method*, Indo Am. J. P. Sci, 2023; 10 (10).

INTRODUCTION:

Analytic method development and validation are key elements of any pharmaceutical development program. HPLC analysis method is developed to identify, quantify or purifying compounds of interest. This technical brief will focus on development and validation activities as applied to drug products.

Method development:

Effective method development ensures that laboratory resources are optimized, while methods meet the objectives required at each stage of drug development. Method validation, required by regulatory agencies at certain stages of the drug approval process, is defined as the “process of demonstrating that analytical procedures are suitable for their intended use”. Understanding of the physical and chemical characteristics of drug allows one to select the most appropriate high performance liquid chromatography method development from the available vast literature. Information concerning the sample, for example, molecular mass, structure and functionality, pKa values and UV spectra, solubility of compound should be compiled. The requirement of removal of insoluble impurities by filtration, centrifugation, dilution or concentration to control the concentration, extraction (liquid or solid phase), derivatization for detection etc. should be checked. For pure compound, the sample solubility should be identified whether it is organic solvent soluble or water soluble, as this helps to select the best mobile phase and column to be used in HPLC method development.

Method development in HPLC can be laborious and time consuming. Chromatographers may spend many hours trying to optimize a separation on a column to accomplish the goals. Even among reversed phase columns, there is astonishing diversity, owing to differences in both base silica and bonded phase characteristics. Many of these show unique selectivity. What is needed is a more informed decision making process for column selection that may be used before the chromatographer enters the laboratory. The method of column selection presented here involves a minimal investment in time initially, with the potential of saving many hours in the laboratory.

Analytic methods are intended to establish the identity, purity, physical characteristics and potency of the drugs that we use. Methods are developed to support drug testing against specifications during manufacturing and quality release operations, as well as during long-term stability studies. Methods that support safety and characterization studies or evaluations of drug performance are also to be

evaluated. Once a stability-indicating method is in place, the formulated drug product can then be subjected to heat and light in order to evaluate the potential degradation of the API in the presence of formulation excipients.

The three critical components for a HPLC method are: sample preparation (% organic, pH, shaking/sonication, sample size, sample age) analysis conditions (%organic, pH, flow rate, temperature, wavelength, and column age), and standardization (integration, wavelength, standard concentration, and response factor correction). During the preliminary method development stage, all individual components should be investigated before the final method optimization. This gives the scientist a chance to critically evaluate the method performance in each component and streamline the final method optimization. The percentage of time spent on each stage is proposed to ensure the scientist will allocate sufficient time to different steps. In this approach, the three critical components for a HPLC method (sample preparation, HPLC analysis and standardization) will first be investigated individually.

Method validation

The validation of an analytical method demonstrates the scientific soundness of the measurement or characterization. It is required to provide validation data throughout the regulatory submission process. The validation practice demonstrates that an analytical method measures the correct substance, in the correct amount, and in the appropriate range for the intended samples. It allows the analyst to understand the behavior of the method and to establish the performance limits of the method. The goal is to identify the critical parameters and to establish acceptance criteria for method system suitability.

Validation is defined by the International Organization for Standardization (ISO) as “verification, where the specified requirements are adequate for an intended use”, where the term verification is defined as “provision of objective evidence that a given item fulfills specified requirements”. The applicability and scope of an analytical method should be defined before starting the validation process. It includes defining the analytes, concentration range, description of equipment and procedures, validation level and criteria required. The validation range is defined by IUPAC as “the interval of analyte concentration within which the method can be regarded as

validated". This range is not the highest and lowest possible levels of the analyte that can be determined by the method. Instead, it is defined on the basis of the intended purpose of the method. The method can be validated for use as a screening (qualitative),

semi-quantitative (5-10ppm) or quantitative method. It can also be validated for use on single equipment, different equipments in the laboratory, different laboratories or even for international use at different climatic and environmental conditions. The criteria of each type of validation will of course be different with the validation level required. The various validation parameters include linearity, accuracy, precision, ruggedness, robustness, LOD, LOQ and selectivity or specificity

MATERIALS AND METHODS:

Triamterene & Furosemide from Sura labs, Water and Methanol for HPLC from LICHROSOLV (MERCK), Acetonitrile for HPLC from Merck.

HPLC METHOD DEVELOPMENT: TRAILS

Preparation of standard solution:

Accurately weigh and transfer 10 mg of Triamterene and Furosemide working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol. Further pipette 0.1ml of the above Triamterene and 0.3ml of the Furosemide stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

Procedure:

Inject the samples by changing the chromatographic conditions and record the chromatograms, note the conditions of proper peak elution for performing validation parameters as per ICH guidelines.

Mobile Phase Optimization:

Initially the mobile phase tried was Methanol: Water and Water: Acetonitrile and Methanol: Phosphate Buffer: ACN with varying proportions. Finally, the mobile phase was optimized to Acetonitrile: Phosphate Buffer in proportion 45:55 v/v respectively.

Optimization of Column:

The method was performed with various columns like C18 column, Symmetry and Zodiac column. Phenomenex Luna C18 (4.6×250mm, 5µm) particle size was found to be ideal as it gave good peak shape and resolution at 1ml/min flow.

OPTIMIZED CONDITIONS:

Instrument used	:	Waters HPLC with auto sampler and PDA Detector 996 model.
Temperature	:	35°C
Column	:	Phenomenex Luna C18 (4.6×250mm, 5µm) particle size
Buffer	:	Dissolve 6.8043 of potassium dihydrogen phosphate in 1000 ml HPLC water and adjust the pH 4.6 with diluted orthophosphoric acid. Filter and sonicate the solution by vacuum filtration and ultra sonication.
pH	:	4.6
Mobile phase	:	Acetonitrile: Phosphate Buffer (45:55 v/v)
Flow rate	:	1ml/min
Wavelength	:	245 nm
Injection volume	:	10 µl
Run time	:	7 min

VALIDATION

PREPARATION OF BUFFER AND MOBILE PHASE:

Preparation of Potassium dihydrogen Phosphate (KH₂PO₄) buffer (pH-4.6):

Dissolve 6.8043 of potassium dihydrogen phosphate in 1000 ml HPLC water and adjust the pH 4.6 with diluted orthophosphoric acid. Filter and sonicate the solution by vacuum filtration and ultra sonication.

Preparation of mobile phase:

Accurately measured 450 ml (45%) of Methanol, 550 ml of Phosphate buffer (55%) were mixed and degassed in digital ultrasonicator for 15 minutes and then filtered through 0.45 µ filter under vacuum filtration.

Diluent Preparation:

The Mobile phase was used as the diluent.

RESULTS AND DISCUSSION:

Optimized Chromatogram (Standard)

Mobile phase	:	Acetonitrile: Phosphate Buffer (pH-4.6) (45:55 v/v)
Column	:	Phenomenex Luna C18 (4.6×250mm, 5µm) particle size
Flow rate	:	1 ml/min
Wavelength	:	245 nm
Column temp	:	35°C
Injection Volume	:	10 µl
Run time	:	7 minutes




Fig:- Optimized Chromatogram
Table: - Peak results for Optimized Chromatogram

S. No	Peak name	R _t	Area	Height	USP Resolution	USP Tailing	USP plate count
1	Triamterene	2.102	765789	69584		0.97	5587.0
2	Furosemide	3.537	2532158	190049	2.97	1.26	5398.0

Observation: From the above chromatogram it was observed that the Triamterene and Furosemide peaks are well separated and they shows proper retention time, resolution, peak tail and plate count. So it's optimized trial.

Optimized Chromatogram (Sample)




Figure:- Optimized Chromatogram (Sample)
Table: Optimized Chromatogram (Sample)

S. No	Peak name	R _t	Area	Height	USP Resolution	USP Tailing	USP plate count
1	Triamterene	2.120	775684	13124		0.99	6365.0
2	Furosemide	3.536	2658478	937405	5.06	1.23	7458.0

Assay (Standard):**Table:- Peak results for assay standard**

Sno	Name	Rt	Area	Height	USP Resolution	USP Tailing	USP plate count	Injection
1	Triamterene	2.102	759868	71255		1.7	5689	1
2	Furosemide	3.537	2458754	215654	2.04	1.6	5362	1
3	Triamterene	2.105	759458	72541		1.7	5748	2
4	Furosemide	3.552	2465885	226565	2.00	1.6	5452	2
5	Triamterene	2.112	759245	72584		1.7	5584	3
6	Furosemide	3.560	2489578	221542	2.04	1.6	5456	3

Acceptance criteria:

- %RSD for sample should be NMT 2
- The %RSD for the standard solution is below 1, which is within the limits hence method is precise.

Assay (Sample):**Table: Peak results for Assay sample**

Sno	Name	Rt	Area	Height	USP Resolution	USP Tailing	USP plate count	Injection
1	Triamterene	2.120	756985	68958		0.98	7253	1
2	Furosemide	3.536	2569856	198564	2.06	1.23	8836	1
3	Triamterene	2.120	758745	69857		1.05	6530	2
4	Furosemide	3.537	2598654	195682	2.04	0.99	7270	2
5	Triamterene	2.102	756848	69588		1.7	7586	3
6	Furosemide	3.537	2587454	192541	2.04	1.6	8371	3


% ASSAY =

$$\frac{\text{Sample area}}{\text{Standard area}} \times \frac{\text{Weight of standard}}{\text{Dilution of standard}} \times \frac{\text{Dilution of sample}}{\text{Weight of sample}} \times \frac{\text{Purity}}{100} \times \frac{\text{Weight of tablet}}{\text{Label claim}} \times 100$$

The % purity of Triamterene and Furosemide in pharmaceutical dosage form was found to be 99.8%.


LINEARITY**Triamterene:**

Concentration µg/ml	Average Peak Area
6	205035
8	381239
10	561128
12	740162
14	909922

**Figure: Calibration Graph for Triamterene**

Furosemide

Concentration µg/ml	Average Peak Area
18	757881
24	757881
30	1458941
36	2132457
42	2901811

**Figure: Calibration Graph for Furosemide****REPEATABILITY****Table: Results of Repeatability for Triamterene:**

Sno	Name	Rt	Area	Height	USP plate count	USP Tailing
1	Triamterene	2.108	766854	702564	5685	1.6
2	Triamterene	2.105	765884	698789	5584	1.4
3	Triamterene	2.113	765842	701235	5521	1.6
4	Triamterene	2.109	768985	700124	5525	1.9
5	Triamterene	2.109	765845	698986	5578	1.7
Mean			766682			
Std. Dev			1357.973			
% RSD			0.177123			

Acceptance criteria:

- %RSD for sample should be NMT 2
- The %RSD for the standard solution is below 1, which is within the limits hence method is precise.

Table:- Results of method precision for Furosemide:

Sno	Name	Rt	Area	Height	USP plate count	USP Tailing
1	Furosemide	3.552	2569865	2231111	5365	1.6
2	Furosemide	3.550	2578474	2674210	5425	1.6
3	Furosemide	3.564	2568985	2231261	5368	1.5
4	Furosemide	3.564	2586845	2421301	5359	1.5
5	Furosemide	3.565	2545898	2324710	5498	1.6
Mean			2570013			
Std. Dev			15309.45			
% RSD			0.595695			

Acceptance criteria:

- %RSD for sample should be NMT 2
- The %RSD for the standard solution is below 1, which is within the limits hence method is precise.

Intermediate precision:**Table-: Results of Intermediate precision for Triamterene**

Sno	Name	Rt	Area	Height	USP plate count	USP Tailing
1	Triamterene	2.108	758955	68986	5785	1.6
2	Triamterene	2.105	759869	68957	5698	1.4
3	Triamterene	2.113	758985	68545	5689	1.6
4	Triamterene	2.109	756894	68952	5781	1.9
5	Triamterene	2.109	759854	68595	5785	1.7
6	Triamterene	2.102	756985	68952	5693	1.6
Mean			758590.3			
Std. Dev			1339.793			
% RSD			0.176616			

Acceptance criteria:

- %RSD of Six different sample solutions should not more than 2.

Table-: Results of Intermediate precision for Furosemide

S.No.	Name	Rt	Area	Height	USP plate count	USP Tailing	USP Resolution
1	Furosemide	3.552	2659852	190025	5485	1.5	2.04
2	Furosemide	3.550	2648574	190048	5421	1.6	2.03
3	Furosemide	3.564	2659865	190054	5468	1.6	2.01
4	Furosemide	3.564	2658547	190078	5487	1.6	2.05
5	Furosemide	3.565	2648981	190016	5492	1.6	2.02
6	Furosemide	3.537	2654652	190057	5463	1.6	2.03
Mean			2655079				
Std. Dev			5242.086				
% RSD			0.197436				

Acceptance criteria:

- %RSD of Six different sample solutions should not more than 2.
- The %RSD obtained is within the limit, hence the method is rugged.

Table: Results of Intermediate precision Day 2 for Triamterene

Sno	Name	Rt	Area	Height	USP plate count	USP Tailing
1	Triamterene	2.102	766895	69858	5586	1.5
2	Triamterene	2.105	765988	69854	5636	1.6
3	Triamterene	2.112	766532	69824	5432	1.6
4	Triamterene	2.113	766214	69875	5468	1.6
5	Triamterene	2.109	765897	69854	5546	1.9
6	Triamterene	2.109	765245	69848	5507	1.7
Mean			766128.5			
Std. Dev			567.7234			
% RSD			0.074103			

Acceptance criteria:

- %RSD of Six different sample solutions should not more than 2.

Table-: Results of Intermediate precision for Furosemide

Sno	Name	Rt	Area	Height	USP plate count	USP Tailing	USP Resolution
1	Furosemide	3.537	2653254	190110	5428	1.6	7.98
2	Furosemide	3.552	2648985	190058	5452	1.6	6.4
3	Furosemide	3.560	2658213	190142	5498	1.6	8.9
4	Furosemide	3.564	2653652	190031	5442	1.5	8.3
5	Furosemide	3.564	2648978	190058	5489	1.5	7.5
6	Furosemide	3.565	2658985	190047	5463	1.6	5.3
Mean			2653678				
Std. Dev			4313.355				
% RSD			0.162543				

Acceptance criteria:

- %RSD of Six different sample solutions should not more than 2
- The %RSD obtained is within the limit, hence the method is rugged.

ACCURACY:**Table-: The accuracy results for Triamterene**

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	392891.7	5	5.027	100.540%	100.351%
100%	781996	10	10.026	100.260%	
150%	1171988	15	15.038	100.253%	

Table-: The accuracy results for Furosemide

%Concentration (at specification Level)	Area	Amount Added (ppm)	Amount Found (ppm)	% Recovery	Mean Recovery
50%	204962	15	15.156	101.040%	100.93%
100%	365018	30	30.378	101.260%	
150%	521064.3	45	45.218	100.484%	

Acceptance Criteria:

- The percentage recovery was found to be within the limit (98-102%).

The results obtained for recovery at 50%, 100%, 150% are within the limits. Hence method is accurate.

Robustness**Triamterene:**

Parameter used for sample analysis	Peak Area	Retention Time	Theoretical plates	Tailing factor
Actual Flow rate of 1.0 mL/min	765789	2.102	5587	1.7
Less Flow rate of 0.9 mL/min	758698	2.330	5458	1.7
More Flow rate of 1.1 mL/min	7689584	1.950	5696	1.7
Less organic phase	758412	2.290	5586	1.4
More organic phase	769852	1.998	5355	1.5

Acceptance criteria:

The tailing factor should be less than 2.0 and the number of theoretical plates (N) should be more than 2000.

Furosemide:

Parameter used for sample analysis	Peak Area	Retention Time	Theoretical plates	Tailing factor
Actual Flow rate of 1.0 mL/min	2532158	3.537	5398	1.6
Less Flow rate of 0.9 mL/min	2458692	3.885	5329	1.7
More Flow rate of 1.1 mL/min	2658642	3.263	5256	1.7
Less organic phase	2452148	4.435	5214	1.2
More organic phase	2653894	3.009	5524	1.0

Acceptance criteria:

The tailing factor should be less than 2.0 and the number of theoretical plates (N) should be more than 2000.

CONCLUSION:

A new method was established for simultaneous estimation of Triamterene and Furosemide by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Triamterene and Furosemide by using Phenomenex Luna C18 (4.6×250mm, 5µm) particle size, flow rate was 1ml/min, mobile phase ratio was (45:55 v/v) Acetonitrile: Phosphate Buffer (pH-4.6 was adjusted with orthophosphoric acid), detection wave length was 245nm.

The instrument used was WATERS HPLC Auto Sampler, Separation module 2695, photo diode array detector 996, Empower-software version-2. The retention times were found to be 2.102mins and 3.537mins. The % purity of Triamterene and Furosemide was found to be 99.8%. The system suitability parameters for Triamterene and Furosemide such as theoretical plates and tailing factor were found to be within limits. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study n Triamterene and Furosemide was found in concentration range of 6µg-14µg and 18µg-42µg and correlation coefficient (r^2) was found to be 0.999 and 0.999, % recovery was found to be 100.351% and 100.93%, %RSD for repeatability was 0.177 and 0.595. The precision study was precise, robust, and repeatable. LOD value was 0.6 and 0.8, and LOQ value was 1.8 and 2.4 respectively.

Hence the suggested RP-HPLC method can be used for routine analysis of Triamterene and Furosemide in API and Pharmaceutical dosage form.

ACKNOWLEDGEMENT

The Authors are thankful to the Management and Principal, Department of Pharmacy, Avanthi Institute of Pharmacy, for extending support to carry out the research work. Finally, the authors express their

gratitude to the Sura Labs, Dilsukhnagar, Hyderabad, for providing research equipment and facilities.

BIBLIOGRAPHY:

1. Dr. Kealey and P.J Haines, Analytical Chemistry, 1st edition, Bios Publisher, (2002), PP 1-7.
2. A.Braithwait and F.J.Smith, Chromatographic Methods, 5th edition, Kluwer Academic Publisher, (1996), PP 1-2.
3. Andrea Weston and Phyllisr. Brown, HPLC Principle and Practice, 1st edition, Academic press, (1997), PP 24-37.
4. Yuri Kazakevich and Rosario Lobrutto, HPLC for Pharmaceutical Scientists, 1st edition, Wiley Interscience A John Wiley & Sons, Inc., Publication, (2007), PP 15-23.
5. Chromatography, (online). URL:<http://en.wikipedia.org/wiki/Chromatography>.
6. Meyer V.R. Practical High-Performance Liquid Chromatography, 4th Ed. England, John Wiley & Sons Ltd, (2004), PP 7-8.
7. Sahajwalla CG a new drug development, vol 141, Marcel Dekker Inc., New York, (2004), PP 421-426.
8. D. H. Shewiy, E. Kaale, P. G. Risha, B. Dejaegher, J. S. Verbeke, Y. V. Heyden, Journal Pharmaceut. Biomed. Anal, **66**, 2012, 11-23.
9. M. D. Rockville, General Tests, Chapter 621 – Chromatography System Suitability, United States Pharmacopeial Convention (USP), USP 31, 2009.
10. FDA Guidance for Industry-Analytical Procedures and Method Validation, Chemistry, Manufacturing, and Controls Documentation, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), 2000.
11. Korany MA, Mahgoub H, Ossama TF, Hadir MM. Application of artificial neural networks for response surface modelling in HPLC method development. J Adv Res, **3**, 2012, 53-63.

12. Swartz ME, Jone MD, Fowler P, Andrew MA. Automated HPLC method development and transfer. *Lc Gc N. Am*, **75**, 2002, 49-50.
13. Synder LR, Kirkland JJ, Glajach JL. X. In *Practical HPLC Methods Development*. John Wiley , New York, **295**, 1997, 643-712.
14. Swartz M, Murphy MB. *New Fronties in Chromatography*. *Am Lab*, **37**, 2005, 22-27.
15. Dolan JW. Peak tailing and resolution. *Lc Gc N. Am*, **20**, 2002, 430-436.
16. Chan CC, Leo YC, Lam H. *Analytical method validation and Instrument Perfomance Validation*. Vol-I, Wiley Interscience, 2004.
17. Shabir GA, Lough WJ., Arain SA, Bradshaw TK. Evaluation and application of best practice in analytical method validation. *J Chromatogr RT*, **30**, 2007, 311-333.
18. Miller JN, Miller JC, *Statistics and chemometrics for analytical chemistry* Harlow, Pearson Prentice Hall, 2005, 263.
19. Huber L. Validation of HPLC methods. *BioPharm. Int*, **12**, 1999, 64-66.